Craig-Hallum says it would be a buyer of CareDx (CDNA) shares today. The firm has learned that Natera (NTRA) is no longer pursuing infringement claims under the ‘544 and ‘180 patents against the current version of AlloSure Kidney. With no claims of ongoing infringement, Natera cannot obtain an injunction on the current version of AlloSure Kidney. Craig-Hallum believes that this news will be a positive catalyst for CareDx shares as the Natera motion was seen by some as an overhang on the stock. The firm has a Buy rating on CareDx shares with a price target of $40.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- CareDx appoints Jing Huang as chief data and artificial intelligence officer
- CareDx announces closure of DOJ investigation with no finding of wrongdoing
- CareDx Arranges Amicable Exit for Executive Alexander Johnson
- CareDx hiring of industry vet Kennedy a positive, says BTIG
- CareDx Announces Key Executive Appointments and Investor Day